Pemigatinib combined with camrelizumab

Pemigatinib, an oral inhibitor of FGFR1, 2, and 3, for the treatment of patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements, based on results from the FIGHT-202 trial. Camrelizumab is a PD-1 monoclonal antibody that has been approved for 8 indications in five major tumor types: lung cancer, liver cancer, esophageal cancer, nasopharyngeal cancer and lymphoma.

这两种药物都是用于治疗癌症的药物，但它们的作用机制和适应症有所不同。如果这两种药物联合使用，可能会产生协同作用，增强抗肿瘤效果。但是，联合使用药物时，可能会增加不良反应的风险。因此，在使用这两种药物之前，应该进行充分的临床评估和风险-效益分析，以确保安全和有效。具体的用药方案和剂量应该根据患者的病情、身体状况和医生的建议来确定。

The original drug Pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 9mg*14 tablets may be around 50,000 yuan, which is expensive. The original drug Pemetinib currently on the market overseas, with a specification of 13.5mg*14 tablets, may cost around RMB 70,000 per box (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold abroad. For example, the price of 4.5mg*14 tablets per box produced by a Laos pharmaceutical factory may be around 1,000 yuan (the price may fluctuate due to exchange rates).